Meropenem-Vaborbactam vs. Best AvailableTherapy for Carbapenem-ResistantEnterobacteriaceae Infections in TANGO II: PrimaryOutcomes by Site of Infection
Abstract Background Meropenem-vaborbactam (M-V) is a β-lactamase inhibitor combination active against Klebsiella pneumoniaecarbapenemase (KPC)-producing CRE. Few clinical trials of new agents have been conducted in patients with CRE. Methods TANGO II is a randomized, Phase 3, open-label trial in pat...
Saved in:
Published in | Open forum infectious diseases Vol. 4; no. suppl_1; pp. S536 - S537 |
---|---|
Main Authors | , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
US
Oxford University Press
01.10.2017
|
Online Access | Get full text |
ISSN | 2328-8957 2328-8957 |
DOI | 10.1093/ofid/ofx163.1397 |
Cover
Abstract | Abstract
Background
Meropenem-vaborbactam (M-V) is a β-lactamase inhibitor combination active against Klebsiella pneumoniaecarbapenemase (KPC)-producing CRE. Few clinical trials of new agents have been conducted in patients with CRE.
Methods
TANGO II is a randomized, Phase 3, open-label trial in patients with infections due to known or suspected CRE, including complicated urinary tract infection (cUTI), acute pyelonephritis (AP), HABP/VABP, bacteremia, or complicated intra-abdominal infection (cIAI). Eligible subjects were randomized 2:1 to monotherapy with M-V or Best Available Therapy (BAT) for 7–14 days. BAT could include (alone or in combination): a carbapenem, aminoglycoside, polymyxin B, colistin, tigecycline or ceftazidime-avibactam (monotherapy only). Enrollment was stratified by infection type and geographic region. Endpoints differed by infection: overall success (clinical cure + microbial eradication) in cUTI/AP, 28-day all-cause mortality in HABP/VABP + bacteremia, and clinical cure in cIAI. It was not powered for inferential statistical testing; results are presented descriptively.
Results
72 patients were enrolled: 43 (59.7%) had baseline CRE and comprised the microbiologic CRE modified intent-to-treat population (mCRE-MITT, primary population). In mCRE-MITT, 20 had bacteremia, 15 had cUTI/AP, 5 had HABP/VABP, and 3 had cIAI.
Conclusion
In this first prospective comparative trial of a β-lactam/β-lactamase inhibitor combination as monotherapy of CRE infections, M-V showed consistent improvement over BAT in efficacy endpoints across infections, and improved safety/tolerability. M-V appears to be an improved treatment option for CRE infections.
Disclosures
R. Wunderink, The Medicines Company: Consultant and Investigator, Consulting fee and Research grant; G. Rahav, MSD: Consultant, Investigator and Speaker’s Bureau, Consulting fee, Research grant and Speaker honorarium; Pfizer: Consultant, Investigator and Speaker’s Bureau, Consulting fee, Research grant and Speaker honorarium; Astellas: Consultant, Investigator and Speaker’s Bureau, Consulting fee, Research grant and Speaker honorarium; A. Mathers, Accelerate Diagnostics: Consultant, Consulting fee; The Medicines Company: Consultant, Consulting fee; Zavante Therapeutics: Research Contractor, Research support; M. Bassetti, MSD: Consultant, Research Contractor and Speaker’s Bureau, Consulting fee, Research grant and Speaker honorarium; Pfizer: Consultant, Research Contractor and Speaker’s Bureau, Consulting fee, Research grant and Speaker honorarium; Astellas: Consultant and Speaker’s Bureau, Consulting fee and Speaker honorarium; AstraZeneca: Consultant and Speaker’s Bureau, Consulting fee and Speaker honorarium; The Medicines Company: Consultant, Consulting fee; Tetraphase: Consultant and Speaker’s Bureau, Consulting fee and Speaker honorarium; Angelini: Consultant and Speaker’s Bureau, Consulting fee and Speaker honorarium; Basilea: Consultant and Speaker’s Bureau, Consulting fee and Speaker honorarium; Achaogen: Consultant, Consulting fee; Paratek: Consultant, Consulting fee; J. Solomkin, Merck: Consultant, Consulting fee; Tetraphase: Consultant, Consulting fee; 3M: Consultant, Consulting fee; Arsanis: Consultant, Consulting fee; Department of Defense: Research Contractor, Research support; E. Alexander, The Medicines Company: Shareholder, Salary; J. S. Loutit, The Medicine’s Company: Employee and Shareholder, Salary; S. Zhang, The Medicines Company: Shareholder, Salary; M. N. Dudley, The Medicine’s Company: Employee and Shareholder, Salary; K. S. Kaye, Xellia: Consultant, Consulting fee; Merck: Consultant and Grant Investigator, Consulting fee and Research support; The Medicines Company: Consultant and Grant Investigator, Consulting fee and Research support
Efficacy by Infection Type
M-V (N = 28)
n/N’ (%)
BAT (N = 15)
n/N’ (%)
Bacteremia + HABP/VABP
All-Cause Mortality, Day 28
4/16 (25.0%)
4/9 (44.4%)
cUTI/AP
Overall Success at End of Therapy (EOT)
8/11 (72.7%)
2/4 (50%)
Overall Success at Test of Cure (TOC, EOT + 7 d)
3/7 (42.9%)*
2/4 (50%)
cIAI
Clinical Cure at TOC
1/1 (100%)
0/2 (0)
*4 M-V subjects were indeterminate/not assessed at TOC.
AEs occurred in 84.4% of M-V patients vs. 92% on BAT. M-V was associated with fewer drug-related AEs (24.4% vs. 44%), severe AEs (13.3% vs. 28%), and serious AEs (33.3% vs. 44%) vs. BAT. |
---|---|
AbstractList | Abstract
Background
Meropenem-vaborbactam (M-V) is a β-lactamase inhibitor combination active against Klebsiella pneumoniaecarbapenemase (KPC)-producing CRE. Few clinical trials of new agents have been conducted in patients with CRE.
Methods
TANGO II is a randomized, Phase 3, open-label trial in patients with infections due to known or suspected CRE, including complicated urinary tract infection (cUTI), acute pyelonephritis (AP), HABP/VABP, bacteremia, or complicated intra-abdominal infection (cIAI). Eligible subjects were randomized 2:1 to monotherapy with M-V or Best Available Therapy (BAT) for 7–14 days. BAT could include (alone or in combination): a carbapenem, aminoglycoside, polymyxin B, colistin, tigecycline or ceftazidime-avibactam (monotherapy only). Enrollment was stratified by infection type and geographic region. Endpoints differed by infection: overall success (clinical cure + microbial eradication) in cUTI/AP, 28-day all-cause mortality in HABP/VABP + bacteremia, and clinical cure in cIAI. It was not powered for inferential statistical testing; results are presented descriptively.
Results
72 patients were enrolled: 43 (59.7%) had baseline CRE and comprised the microbiologic CRE modified intent-to-treat population (mCRE-MITT, primary population). In mCRE-MITT, 20 had bacteremia, 15 had cUTI/AP, 5 had HABP/VABP, and 3 had cIAI.
Conclusion
In this first prospective comparative trial of a β-lactam/β-lactamase inhibitor combination as monotherapy of CRE infections, M-V showed consistent improvement over BAT in efficacy endpoints across infections, and improved safety/tolerability. M-V appears to be an improved treatment option for CRE infections.
Disclosures
R. Wunderink, The Medicines Company: Consultant and Investigator, Consulting fee and Research grant; G. Rahav, MSD: Consultant, Investigator and Speaker’s Bureau, Consulting fee, Research grant and Speaker honorarium; Pfizer: Consultant, Investigator and Speaker’s Bureau, Consulting fee, Research grant and Speaker honorarium; Astellas: Consultant, Investigator and Speaker’s Bureau, Consulting fee, Research grant and Speaker honorarium; A. Mathers, Accelerate Diagnostics: Consultant, Consulting fee; The Medicines Company: Consultant, Consulting fee; Zavante Therapeutics: Research Contractor, Research support; M. Bassetti, MSD: Consultant, Research Contractor and Speaker’s Bureau, Consulting fee, Research grant and Speaker honorarium; Pfizer: Consultant, Research Contractor and Speaker’s Bureau, Consulting fee, Research grant and Speaker honorarium; Astellas: Consultant and Speaker’s Bureau, Consulting fee and Speaker honorarium; AstraZeneca: Consultant and Speaker’s Bureau, Consulting fee and Speaker honorarium; The Medicines Company: Consultant, Consulting fee; Tetraphase: Consultant and Speaker’s Bureau, Consulting fee and Speaker honorarium; Angelini: Consultant and Speaker’s Bureau, Consulting fee and Speaker honorarium; Basilea: Consultant and Speaker’s Bureau, Consulting fee and Speaker honorarium; Achaogen: Consultant, Consulting fee; Paratek: Consultant, Consulting fee; J. Solomkin, Merck: Consultant, Consulting fee; Tetraphase: Consultant, Consulting fee; 3M: Consultant, Consulting fee; Arsanis: Consultant, Consulting fee; Department of Defense: Research Contractor, Research support; E. Alexander, The Medicines Company: Shareholder, Salary; J. S. Loutit, The Medicine’s Company: Employee and Shareholder, Salary; S. Zhang, The Medicines Company: Shareholder, Salary; M. N. Dudley, The Medicine’s Company: Employee and Shareholder, Salary; K. S. Kaye, Xellia: Consultant, Consulting fee; Merck: Consultant and Grant Investigator, Consulting fee and Research support; The Medicines Company: Consultant and Grant Investigator, Consulting fee and Research support
Efficacy by Infection Type
M-V (N = 28)
n/N’ (%)
BAT (N = 15)
n/N’ (%)
Bacteremia + HABP/VABP
All-Cause Mortality, Day 28
4/16 (25.0%)
4/9 (44.4%)
cUTI/AP
Overall Success at End of Therapy (EOT)
8/11 (72.7%)
2/4 (50%)
Overall Success at Test of Cure (TOC, EOT + 7 d)
3/7 (42.9%)*
2/4 (50%)
cIAI
Clinical Cure at TOC
1/1 (100%)
0/2 (0)
*4 M-V subjects were indeterminate/not assessed at TOC.
AEs occurred in 84.4% of M-V patients vs. 92% on BAT. M-V was associated with fewer drug-related AEs (24.4% vs. 44%), severe AEs (13.3% vs. 28%), and serious AEs (33.3% vs. 44%) vs. BAT. |
Author | Wunderink, Richard Giamarellos-Bourboulis, Evangelos Loutit, Jeffrey S Alexander, Elizabeth Solomkin, Joseph Rahav, Galia Kaye, Keith S Dudley, Michael N Mathers, Amy Bassetti, Matteo Zhang, Shu |
Author_xml | – sequence: 1 givenname: Richard surname: Wunderink fullname: Wunderink, Richard organization: Northwestern University Feinberg School of Medicine, Chicago, Illinois – sequence: 2 givenname: Evangelos surname: Giamarellos-Bourboulis fullname: Giamarellos-Bourboulis, Evangelos organization: Athens Medical School, Athens, Greece – sequence: 3 givenname: Galia surname: Rahav fullname: Rahav, Galia organization: Sheba Medical Center, Tel Hashomer, Israel – sequence: 4 givenname: Amy surname: Mathers fullname: Mathers, Amy organization: University of Virginia Health System, Charlottesville, Virginia – sequence: 5 givenname: Matteo surname: Bassetti fullname: Bassetti, Matteo organization: San Martino Hospital, Genova, Italy – sequence: 6 givenname: Joseph surname: Solomkin fullname: Solomkin, Joseph organization: University of Cincinnati, Cincinnati, Ohio – sequence: 7 givenname: Elizabeth surname: Alexander fullname: Alexander, Elizabeth organization: The Medicines Company, Parsippany, New Jersey – sequence: 8 givenname: Jeffrey S surname: Loutit fullname: Loutit, Jeffrey S organization: The Medicines Company, San Diego, California – sequence: 9 givenname: Shu surname: Zhang fullname: Zhang, Shu organization: The Medicines Company, Parsippany, New Jersey – sequence: 10 givenname: Michael N surname: Dudley fullname: Dudley, Michael N organization: The Medicines Company, San Diego, California – sequence: 11 givenname: Keith S surname: Kaye fullname: Kaye, Keith S organization: University of Michigan Medical School, Ann Arbor, Michigan |
BookMark | eNqNkE1v1DAQQC1UJNrSO0ffqyzjOF_mtl2VslJhEd1yjSbesWqUtSPbW9hfwt8lUZBAPUAvM6PRvLHnnbET5x0x9kbAQoCSb72xuzH8EJVcCKnqF-w0l3mTNaqsT_6qX7GLGL8BgBBQQq1O2c-PFPxAjvbZV-x86FAn3PPHuOBXFBNfPqLtsetp-0ABhyM3PvAVjnMz9IWijQldunZp3DThFCxqQuJrZ0gn613k1vHt8tPNhq_X7_jnYPcYjptD0n5PkXdHfmcTcW_-IK_ZS4N9pIvf-Zzdv7_erj5kt5ub9Wp5m2lRVXVW6k6CQqAGS4n5risMlnWJTaFUoRoYGxXtQBmAstBVXknYNUVeooFCVqaW50zMew9uwON37Pt2mL_XCmgnue0kt53ltpPckYGZ0cHHGMg8B6meINomnA5NYRT8L_ByBv1h-P8zvwDo06QE |
CitedBy_id | crossref_primary_10_1128_AAC_01551_18 crossref_primary_10_2147_IDR_S187360 crossref_primary_10_1007_s40265_019_1054_3 |
ContentType | Journal Article |
Copyright | The Author 2017. Published by Oxford University Press on behalf of Infectious Diseases Society of America. 2017 |
Copyright_xml | – notice: The Author 2017. Published by Oxford University Press on behalf of Infectious Diseases Society of America. 2017 |
DBID | TOX AAYXX CITATION ADTOC UNPAY |
DOI | 10.1093/ofid/ofx163.1397 |
DatabaseName | Oxford Journals Open Access Collection CrossRef Unpaywall for CDI: Periodical Content Unpaywall |
DatabaseTitle | CrossRef |
DatabaseTitleList | |
Database_xml | – sequence: 1 dbid: TOX name: Oxford Journals Open Access (Activated by CARLI) url: https://academic.oup.com/journals/ sourceTypes: Publisher |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
DocumentTitleAlternate | ID Week 2017 Abstracts |
EISSN | 2328-8957 |
EndPage | S537 |
ExternalDocumentID | 10.1093/ofid/ofx163.1397 10_1093_ofid_ofx163_1397 |
GroupedDBID | 0R~ 53G 5VS AAFWJ AAMVS AAPPN AAPXW AAVAP ABDBF ABPTD ABXVV ACGFS ADBBV ADHZD ADPDF ADRAZ AENZO AFPKN AFULF ALMA_UNASSIGNED_HOLDINGS ALUQC AOIJS BAWUL BAYMD BCNDV BTTYL CIDKT DIK EBS EJD GROUPED_DOAJ H13 HYE IAO KQ8 KSI M48 M~E O9- OAWHX OJQWA OK1 OVD OVEED PEELM ROL ROX RPM TEORI TJX TOX 7X7 8C1 8FI 8FJ AAYXX ABEJV ABGNP ABUWG ACUHS AFKRA AMNDL BENPR CCPQU CITATION FYUFA HMCUK PHGZM PHGZT PIMPY PJZUB PPXIY PUEGO UKHRP ADTOC IHR ITC UNPAY |
ID | FETCH-LOGICAL-c1667-5cb309a0e8a53a2db4fa575a84994980db46ed09f0054c62630d8425af0436f73 |
IEDL.DBID | M48 |
ISSN | 2328-8957 |
IngestDate | Tue Aug 19 19:32:58 EDT 2025 Thu Apr 24 23:03:38 EDT 2025 Wed Oct 01 04:14:40 EDT 2025 Wed Aug 28 03:26:17 EDT 2024 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | suppl_1 |
Language | English |
License | This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c1667-5cb309a0e8a53a2db4fa575a84994980db46ed09f0054c62630d8425af0436f73 |
OpenAccessLink | https://dx.doi.org/10.1093/ofid/ofx163.1397 |
ParticipantIDs | unpaywall_primary_10_1093_ofid_ofx163_1397 crossref_primary_10_1093_ofid_ofx163_1397 crossref_citationtrail_10_1093_ofid_ofx163_1397 oup_primary_10_1093_ofid_ofx163_1397 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2017-10-01 |
PublicationDateYYYYMMDD | 2017-10-01 |
PublicationDate_xml | – month: 10 year: 2017 text: 2017-10-01 day: 01 |
PublicationDecade | 2010 |
PublicationPlace | US |
PublicationPlace_xml | – name: US |
PublicationTitle | Open forum infectious diseases |
PublicationYear | 2017 |
Publisher | Oxford University Press |
Publisher_xml | – name: Oxford University Press |
SSID | ssj0001105079 |
Score | 2.0329378 |
Snippet | Abstract
Background
Meropenem-vaborbactam (M-V) is a β-lactamase inhibitor combination active against Klebsiella pneumoniaecarbapenemase (KPC)-producing CRE.... |
SourceID | unpaywall crossref oup |
SourceType | Open Access Repository Enrichment Source Index Database Publisher |
StartPage | S536 |
Title | Meropenem-Vaborbactam vs. Best AvailableTherapy for Carbapenem-ResistantEnterobacteriaceae Infections in TANGO II: PrimaryOutcomes by Site of Infection |
URI | https://academic.oup.com/ofid/article-pdf/4/suppl_1/S536/20430390/ofx163.1397.pdf |
UnpaywallVersion | publishedVersion |
Volume | 4 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
journalDatabaseRights | – providerCode: PRVAFT databaseName: Colorado Digital library customDbUrl: eissn: 2328-8957 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0001105079 issn: 2328-8957 databaseCode: KQ8 dateStart: 20140101 isFulltext: true titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html providerName: Colorado Alliance of Research Libraries – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 2328-8957 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0001105079 issn: 2328-8957 databaseCode: DOA dateStart: 20140101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVEBS databaseName: Academic Search Ultimate customDbUrl: https://search.ebscohost.com/login.aspx?authtype=ip,shib&custid=s3936755&profile=ehost&defaultdb=asn eissn: 2328-8957 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0001105079 issn: 2328-8957 databaseCode: ABDBF dateStart: 20140901 isFulltext: true titleUrlDefault: https://search.ebscohost.com/direct.asp?db=asn providerName: EBSCOhost – providerCode: PRVBFR databaseName: Free Medical Journals customDbUrl: eissn: 2328-8957 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0001105079 issn: 2328-8957 databaseCode: DIK dateStart: 20140101 isFulltext: true titleUrlDefault: http://www.freemedicaljournals.com providerName: Flying Publisher – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 2328-8957 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0001105079 issn: 2328-8957 databaseCode: M~E dateStart: 20140101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre – providerCode: PRVAQN databaseName: PubMed Central customDbUrl: eissn: 2328-8957 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0001105079 issn: 2328-8957 databaseCode: RPM dateStart: 20140101 isFulltext: true titleUrlDefault: https://www.ncbi.nlm.nih.gov/pmc/ providerName: National Library of Medicine – providerCode: PRVOVD databaseName: Journals@Ovid LWW All Open Access Journal Collection Rolling customDbUrl: eissn: 2328-8957 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0001105079 issn: 2328-8957 databaseCode: OVEED dateStart: 20140301 isFulltext: true titleUrlDefault: http://ovidsp.ovid.com/ providerName: Ovid – providerCode: PRVASL databaseName: Oxford Journals Open Access (Activated by CARLI) customDbUrl: eissn: 2328-8957 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0001105079 issn: 2328-8957 databaseCode: TOX dateStart: 20140101 isFulltext: true titleUrlDefault: https://academic.oup.com/journals/ providerName: Oxford University Press – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 2328-8957 dateEnd: 20241001 omitProxy: true ssIdentifier: ssj0001105079 issn: 2328-8957 databaseCode: 7X7 dateStart: 20140401 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: http://www.proquest.com/pqcentral?accountid=15518 eissn: 2328-8957 dateEnd: 20241001 omitProxy: true ssIdentifier: ssj0001105079 issn: 2328-8957 databaseCode: BENPR dateStart: 20140401 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: Public Health Database customDbUrl: eissn: 2328-8957 dateEnd: 20241001 omitProxy: true ssIdentifier: ssj0001105079 issn: 2328-8957 databaseCode: 8C1 dateStart: 20140401 isFulltext: true titleUrlDefault: https://search.proquest.com/publichealth providerName: ProQuest – providerCode: PRVFZP databaseName: Scholars Portal Journals: Open Access customDbUrl: eissn: 2328-8957 dateEnd: 20250831 omitProxy: true ssIdentifier: ssj0001105079 issn: 2328-8957 databaseCode: M48 dateStart: 20141201 isFulltext: true titleUrlDefault: http://journals.scholarsportal.info providerName: Scholars Portal |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lj9owELa6IHV7qfpU2XaRD3tppbBpyItK1QoQ26USD1GouEVjZyIhhcCSQOGX9O92HLu7rYT6uPiQjBPFnzP-7PF8ZuwiIc_oBYjk_QAs1_PAEuiAFWNg01wMpVNmpQ2G_s3M_Tz35vfp0aYB86NTO3We1GyTNva3hyv64T8aMaRLQiGmYk_UoqEIzQmr0rjkqD4-MGS_XHEhKmGX4nvEIkIrbHmBiVsee8hv45TOfTvdZms4fIM0_WUIun7CHhvuyNsa7KfsAWbP2MOBiY4_Z98HqJbWM1xaXxW2AmQBS77LG7xDzp-3d7BIVarUVEsJcCKsvKsCDrrSBHPFJrOi3CmwElrIGSQC8r7ZtJXlfJHxaXv4acT7_Q98rNUqRtuCui7mXBz4F2KxfJXcV3nBZte9affGMgcvWPK9T47Tk6Jpt8DGELwmOLFwEyBaByFNj9xWaNMFH2O7lSjCJ5WejR2rcB4kStA-CZovWSVbZfiKcekIRAmh8GXsgi9Duo8OkSYXpEgCt8YufzZzJI0quTocI410dLwZKWAiDUykgKmxt3c11vob_2B7Qcj9g9m7O2j_anz2H-9_zR45igaUm__esEqx2eI5kZhC1Fm10xuOJ_VyEaBe9lQqp6P5DyqY9fc |
linkProvider | Scholars Portal |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Meropenem-Vaborbactam+vs.+Best+AvailableTherapy+for+Carbapenem-ResistantEnterobacteriaceae+Infections+in+TANGO+II%3A+PrimaryOutcomes+by+Site+of+Infection&rft.jtitle=Open+forum+infectious+diseases&rft.au=Wunderink%2C+Richard&rft.au=Giamarellos-Bourboulis%2C+Evangelos&rft.au=Rahav%2C+Galia&rft.au=Mathers%2C+Amy&rft.pub=Oxford+University+Press&rft.eissn=2328-8957&rft.volume=4&rft.issue=suppl_1&rft.spage=S536&rft.epage=S537&rft_id=info:doi/10.1093%2Fofid%2Fofx163.1397&rft.externalDocID=10.1093%2Fofid%2Fofx163.1397 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2328-8957&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2328-8957&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2328-8957&client=summon |